|
注册号: Registration number: |
ChiCTR1800014786 |
|
最近更新日期: Date of Last Refreshed on: |
2018-02-05 17:37:15 |
|
注册时间: Date of Registration: |
2018-02-05 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
心衰注册研究 |
|
Public title: |
Heart failure registry of health outcomes study |
|
注册题目简写: |
HERO |
|
English Acronym: |
HERO |
|
研究课题的正式科学名称: |
心力衰竭诊疗现状和队列研究 |
|
Scientific title: |
The diagnosis and treatment status of heart failure and cohort study |
|
研究课题代号(代码): Study subject ID: |
国家十三五重点研发计划(项目编号2016YFC1301000) |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李黎 |
研究负责人: |
董建增 |
|
Applicant: |
Li Li |
Study leader: |
Jianzeng Dong |
|
申请注册联系人电话: Applicant telephone: |
+86 13703840917 |
研究负责人电话:
Study leader's |
+86 13911828375 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
109234191@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
jz_dong@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市建设东路1号 |
研究负责人通讯地址: |
河南省郑州市建设东路1号 |
|
Applicant address: |
1 Jianshe Road, Zhengzhou, He'nan, China |
Study leader's address: |
1 Jianshe Road, Zhengzhou, He'nan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
郑州大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Zhengzhou University |
||
|
研究负责人所在单位: |
郑州大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Zhengzhou University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2017-KY-06 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
郑州大学第一附属医院科研和临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Ethics committee on scientific research and clinical trials of The First Affiliated Hospital of Zhengzhou University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2017-09-26 00:00:00 | ||
|
伦理委员会联系人: |
田丽 |
||
|
Contact Name of the ethic committee: |
Li Tian |
||
|
伦理委员会联系地址: |
河南省郑州市建设东路1号 |
||
|
Contact Address of the ethic committee: |
1 Jianshe Road, Zhengzhou, He'nan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
首都医科大学附属北京安贞医院/郑州大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Beijing Anzhen Hospital,Capital Medical University/ The First Affiliated Hospital of Zhengzhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市朝阳区安贞路2号/河南省郑州市建设东路1号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Anzhen Road, Chaoyang Disreict, Beijing, China / 1 Jianshe Road, Zhengzhou, He'nan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家十三五重点研发计划(项目编号2016YFC1301000) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Keypoint Research and invention Program of China (Project No. 2016YFC1301000) |
||||||||||||||||||||||
|
研究疾病: |
心力衰竭 |
||||||||||||||||||||||
|
Target disease: |
heart failure |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1描述河南地区因心衰住院患者的基本情况、临床特点、病因组成、疾病花费及负担。 2描述不同医院对心衰的临床诊断、临床治疗情况,评估目前治疗方法与指南的差距,确定影响差距的原因,为实施下一步的干预计划做好准备。 3评估患者住院期间以及出院后90天再住院率以及死亡率,判断预后及死亡相关因素。 4评价患者治疗依从性和长期预后的影响因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To describe the basic situation, clinical characteristics, etiology, disease expenditure and burden of hospitalized patients caused by HF in Henan; 2. To describe the clinical diagnosis and treatment status of HF in different hospitals, assess the gap between current treatment and guidelines, identify the causes of the gap and prepare for the implementation of the next intervention plan; 3. To assess the re-hospitalization and mortality rates, as well as prognostic and death-related factors when patients in and out of hospital(90 days); 4. To assess the treatment compliance of patients and factors that influencing the long-term prognosis. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
本研究不排除任何患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
No patient is excluded in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-11-20 00:00:00至 To 2018-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2017-11-20 00:00:00 至 To 2018-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
我们共有73家合作医院,其中8家省级医院,22家市级医院,43家县级医院。按照春夏秋冬的分四次,分7组,每次同时调查10-11家医院。随机创建7组,3中不同类别(省、市、县)的医院序号分别为4(1、3、6),1(2、3、6),1(1、4、6),1(1、3、7)。包括在每组中的医院是随机的,同时7组的顺序也是随机的。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The study will be performed in 73 representative hospitals in Henan(8 provincial hospital+22 municipal hospital+43 county hospital).According to spring, summer, autumn and winter, all the hospital were divided into 7 groups, each time, 10 to 11 hospitals were investigated.Randomly create 7 groups, in which the number |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
根据要求 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
on request |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1数据的采集:数据的采集包括基线资料的采集和随访资料的采集。基线数据的收集将在各个研究医院病房内由经过培训的医生进行。基线数据收集人员不直接参与科室心衰患者的临床诊疗过程。基线CRF表通过电子化数据采集系统(EDC系统)录入填写。随访资料的采集将由经过培训的随访护士完成,采用电话随访的形式,填写随访CRF表,随后录入电子化数据采集系统(EDC系统)。2数据的管理 专业的数据管理团队管理数据的质量,提出和监督解决数据质疑。数据管理团队负责督促数据收集团队在患者出院前将所有表格完成,并叮嘱其在完成的表格中签名及完成日期。数据管理组主要调查人员或授权代表将原始资料对CRF表进行核对,检查完成中的CRF表中的缺失数据及明显错误。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
1 Data collection It include collection of clinical baseline data and collection of follow-up data.The clinical baseline data will be collected in the hospital wards.The staffs who are responsible for the data collection do not participate in the diagnostic and treatment progress of HF patients. The baseline CRF will be recorded by the EDC(Electronic Data Capture,EDC) system.The trained follow-up nurses are responsible for the Collection of follow-up data.The patients are followed through telephone remote consultation.The follow-up CRF will be recorded by the EDC(Electronic Data Capture,EDC) system. 2 Data management There is professional data management team to manage the quality of the data, propose and supervise the solution of data doubt. Data management team is responsible for urging data collecting team to finish all tables, including signature and data recording. Major investigators will check original data and CRF tables to distinguish whether there is missing data and obvious fault in the CRF tables. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |